Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billio | South Korean contract manufacturer Samsung Biologics has tapped into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion Swiss francs ($1.8 billion).
658 words~3 min read
